In the latest close session, CRISPR Therapeutics AG (CRSP) was down 5.44% at $49.93. This move lagged the S&P 500's daily loss of 0.08%. On the other hand, the Dow registered a loss of 0.61%, and the ...

Cathie Wood’s ARK Invest added to several beaten-down technology and biotech names while trimming positions elsewhere. The investment manager made a notable purchase in gene-editing company CRISPR ...

CRISPR Therapeutics (NASDAQ:CRSP) is one of the best stocks for 20 years. On February 12, CRISPR Therapeutics announced its ...

Emerging research in cellular reprogramming, gene editing, and regenerative medicine is driving interest in preventive longevity medicine. Some researchers argue aging may be treated as a modifiable ...

I still remember the first time I saw a smartphone, back in 2007, at a tech conference in Berlin. A colleague, Markus, pulled ...

The Ark Innovation ETF is Cathie Wood's flagship fund and is heavily weighted toward innovative growth bets. The ETF recently purchased Figma, CRISPR Therapeutics, and CoreWeave. Here's why these ...

They're names worth holding for far longer, but the coming decade could prove particularly fruitful for these companies.

Thousands of residents were faced with outages in the South Australian town of Port Pirie after a severe thunderstorm and hail destroyed roofs as well as bringing down trees and powerlines. Foxes kill ...

Lipid nanoparticles, or LNPs, best known as the delivery vehicle for the COVID-19 mRNA vaccines received by billions of people, are now at the center of a much larger medical revolution. Researchers ...

ARK Invest purchased ~281K CRISPR Therapeutics (CRSP) shares worth $14.82M after a 10% drop triggered by a $350M private offering announcement.

Drug delivery researchers have vastly improved the potential of genetic therapies by overcoming the challenge of consistently getting genes and gene-editing tools where they need to be within cells.